Checking Bone and Joint Health in Hemophilia A Patients on rFVIIIFc
Checks bone and joint health in people with severe hemophilia A using blood markers.
Plain-language title generated from the registry record
Registry title: A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)
Key facts
- Where
- Taipei, TaiwanSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with severe hemophilia A, or moderate hemophilia A with joint damage, who are now on regular rFVIIIFc treatment and had a year of regular treatment with a standard half-life product before.
- Age
- All ages.
- Sex
- Males only.
- Disease stage
- Severe hemophilia A, or moderate hemophilia A with hemophilic arthropathy (joint damage).
- Earlier treatment
- Currently on regular rFVIIIFc prophylaxis. Must have a medical record of one year of regular prophylaxis with a standard half-life product before.
Main reasons for not taking part
- Taking part in other interventional studies
- Current inhibitors
- Major neurological disease in the past (for example stroke, Parkinson's disease, neuropathy)
- Major psychiatric disease in the past (for example schizophrenia, bipolar disorder)
- Significantly impaired vision or hearing
Read by machine on 12 November 2026.
Where in Taiwan
- Tri-Service General Hospital Hemophilia Care CenterTaipei, TaiwanContact: Yeu-Chin chenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tri-Service General Hospital (TSGH)
- Trial code
- NCT05981274
- Record updated
- 10 April 2024
- Original description
Study Objectives*Read full original descriptionShow less
A Prospective and Retrospective Interventional Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)
Study Objectives*
1. Provide a systematic evaluation of the treatment outcomes in patients with hemophilia A 2. Emphasize the importance and clinical benefits of rFVIII-Fc in joint and bone health. 3. Compare the clinical outcomes from 1 year before and after switching to EHL. 4. Exploratory: Identify biomarkers that could provide more useful and convenient evaluations of joint and bone health. (Time-saving and easy to monitor)
Inclusion: Patients with severe hemophilia A (all ages); Patients with moderate type hemophilia A with hemophilic arthropathy; Currently on rFVIIIFc regular prophylaxis and have previous medical record with regular prophylaxis with standard half-life product for one year; Able and willing to undergo joint and bone examinations.
Exclusion: Patients with current inhibitors; History of major neurological disease (eg. Stroke, Parkinson's disease, neuropathy, etc.); History of major psychiatric disease (eg. Schizophrenia, bipolar disorder); Participants of other interventional studies; Significantly impaired vision/hearing.